×
Home Companies Industry Politics Money Opinion LoungeMultimedia Science Education Sports TechnologyConsumerSpecialsMint on Sunday
×

Glenmark’s new pain drug finishes phase-I trial

Glenmark’s new pain drug finishes phase-I trial
Comment E-mail Print Share
First Published: Mon, Jul 25 2011. 11 58 PM IST
Updated: Mon, Jul 25 2011. 11 57 PM IST
Mumbai: Glenmark Pharmaceuticals Ltd on Monday said it has completed the phase-I trial of its new chronic pain drug candidate—GRC 15300, which has been out-licensed to French drug maker Sanofi SA for a total milestone valuation of $325 million (Rs 1,443 crore).
Glenmark in a statement said it is the first such pain drug entering clinical trials. It also said plans are in place to initiate clinical proof of concept studies in neuropathic pain indication.
GRC 15300, a potential next-generation treatment for various ailments, including diabetic neuropathic pain and osteoarthritic pain, was licensed by Sanofi for the rights of all therapeutic indications in May.
ch.unni@livemint.com
Comment E-mail Print Share
First Published: Mon, Jul 25 2011. 11 58 PM IST